Liraglutide Compassionate Use and Expanded Access: A 2026 Guide

What "Compassionate Use" Actually Means for Liraglutide

Compassionate use, formally called Expanded Access under 21 CFR Part 312, Subpart I, allows patients to receive an investigational drug outside a clinical trial when no comparable alternative exists and the potential benefit outweighs the risk. The FDA defines three tiers: individual patient access, intermediate-size population access, and widespread treatment IND.

Liraglutide does not qualify for any of these tiers. Victoza received full FDA approval for type 2 diabetes in January 2010, and Saxenda received approval for chronic weight management in December 2014. Both approvals are documented in FDA's drug database. Because the drug is commercially available for its labeled indications, the FDA will not grant a compassionate-use IND for those same uses.

When Expanded Access Could Apply to Liraglutide

There is one narrow scenario where an individual IND might still be relevant: an off-label indication being studied in an active trial, such as non-alcoholic steatohepatitis (NASH) or Parkinson's disease neuroprotection. A small randomized trial published in the New England Journal of Medicine (N=62) found liraglutide 1.2 mg daily slowed Parkinson's progression on the MDS-UPDRS Part III motor scale compared to placebo at 52 weeks (Athauda et al., NEJM 2017). For an unapproved indication like that, a treating neurologist could submit an individual IND to the FDA. The process takes about 30 days for FDA review.

What Patients Usually Mean When They Search "Compassionate Use"

Most patients typing "liraglutide compassionate use" are actually looking for free or deeply discounted access because they cannot afford the drug. That is a different problem with several real solutions, covered in detail below.

The Novo Nordisk Patient Assistance Program (PAP)

Novo Nordisk operates a direct patient assistance program called the Novo Nordisk Patient Assistance Program that provides Victoza and Saxenda at no cost to qualifying patients. Eligibility generally requires US residency, no adequate prescription drug coverage, and household income at or below 400% of the Federal Poverty Level (roughly $60,240 for a single person in 2025).

How to Apply

Applications are submitted through NovoCare, Novo Nordisk's patient support platform. Your prescribing clinician must complete a section of the form confirming medical necessity. Processing typically takes two to four weeks, and approved patients receive a 90-day supply by mail. Reapplication is required annually.

Income Limits and What to Do If You Exceed Them

Patients above the 400% FPL threshold but below roughly 600% FPL may still qualify for a partial discount through NovoCare's co-pay assistance tier. Income documentation (most recent federal tax return or current pay stubs) is required. If your income exceeds those thresholds entirely, the Saxenda Savings Card and third-party discount programs covered below are the next steps.

The Saxenda Savings Card and Victoza Co-Pay Card

For commercially insured patients, Novo Nordisk offers a co-pay savings card that can reduce monthly Saxenda costs to approximately $99 for eligible patients. The program details are posted on the official Saxenda site. Patients pay a fixed co-pay and Novo Nordisk covers the remainder up to the card's annual maximum benefit.

The Victoza co-pay card works similarly for T2D patients, with a different cap structure. Key restrictions apply:

• The cards cannot be used by patients enrolled in Medicare, Medicaid, or any federal or state government insurance program.
• Patients enrolled in health plans with a liraglutide exclusion on formulary cannot use the card to override that exclusion at most retail pharmacies.
• Annual maximum benefits reset each January 1.

A 2023 JAMA Internal Medicine analysis found that manufacturer co-pay cards for GLP-1 receptor agonists reduced average monthly patient spending by 74% in commercially insured populations, though savings were much smaller for patients with high-deductible health plans during the deductible phase (Dusetzina et al., JAMA Intern Med 2023).

Generic Liraglutide: What Is Available in 2026

The field for liraglutide generics shifted meaningfully in 2024. The FDA approved the first follow-on injectable liraglutide product referencing NDA 209637, clearing the path for lower-cost alternatives to enter pharmacy shelves. Generic injectable biologics are complex to manufacture, so price reductions are typically 20 to 40% below brand at launch rather than the 80 to 90% seen with small-molecule generics.

How Generic Liraglutide Differs from Biosimilar

Liraglutide is a 31-amino-acid GLP-1 analog that is chemically synthesized rather than produced in living cells. The FDA classifies it as a small molecule under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman), not under the Biologics Price Competition and Innovation Act (BPCIA). This distinction matters because Hatch-Waxman generics require bioequivalence data only, not the more extensive comparability package needed for biologics. That lower regulatory bar should accelerate the entry of multiple generic manufacturers.

Checking Generic Availability at Your Pharmacy

GoodRx, Cost Plus Drugs (Mark Cuban's transparency pharmacy), and Amazon Pharmacy all list real-time pricing for liraglutide. As of early 2026, Cost Plus Drugs lists the 18 mg/3 mL Saxenda pen at prices ranging from $340 to $480 per pen depending on the generic manufacturer, compared to the $1,400 brand list price. Always confirm with your pharmacy that the generic version is in stock before your prescriber writes the prescription; ask them to write "DAW-0" (dispense as written, generic acceptable) or simply "generic acceptable" on the script.

HSA and FSA Eligibility for Liraglutide

Yes. Liraglutide qualifies for payment through a Health Savings Account (HSA) or Flexible Spending Account (FSA). IRS Publication 502 defines eligible medical expenses to include prescription drugs obtained legally. Because Victoza and Saxenda both require a prescription, they meet this definition.

Practical Tips for Using HSA/FSA

Paying with an HSA debit card at the pharmacy is the most direct method. If you pay out of pocket first, keep the pharmacy receipt and the Explanation of Benefits from your insurer, then submit for reimbursement through your HSA or FSA administrator's online portal.

One underused strategy: when your deductible has not yet been met, pay for liraglutide using HSA funds (pre-tax dollars) instead of a personal credit card. On a $1,200 monthly liraglutide expense and a 25% marginal tax rate, that saves approximately $300 per month in after-tax cost.

FSA accounts have a "use it or lose it" rule at year-end (with a grace period or $610 rollover option depending on plan design). If you anticipate ongoing liraglutide use, elect FSA contributions accordingly during open enrollment.

State Medicaid Coverage and Low-Income Pathways

Medicaid coverage of liraglutide varies by state and by formulation.

Victoza (T2D Indication)

Most state Medicaid programs cover Victoza for type 2 diabetes, often with prior authorization requiring documentation that metformin and a sulfonylurea have been tried first. The ADA Standards of Care 2024 recommend GLP-1 receptor agonists as preferred add-on therapy in T2D patients with established cardiovascular disease or high CV risk, citing the LEADER trial results. This guideline language strengthens prior authorization appeals.

Saxenda (Obesity Indication)

Saxenda coverage through Medicaid is patchier. As of 2025, fewer than half of state Medicaid programs cover anti-obesity medications at all. The TREAT and CARE Act, introduced in the 118th Congress, would require Medicaid to cover FDA-approved anti-obesity drugs, but it had not been enacted as of this writing. Patients denied Medicaid coverage for Saxenda should request a formal denial letter and appeal citing the USPSTF Grade B recommendation for intensive behavioral intervention for obesity, which some plans interpret as extending to pharmacotherapy adjuncts.

Third-Party Discount Programs and Online Pharmacies

Several third-party programs can lower liraglutide costs outside the manufacturer's own programs.

GoodRx and Similar Discount Cards

GoodRx negotiates discounted cash prices with pharmacy chains. For liraglutide 18 mg/3 mL (the Saxenda 5-pen box), GoodRx prices at major chains ranged from $780 to $960 in early 2026, representing a 30 to 40% discount off list price. These cards cannot be combined with insurance at the same transaction, but they are useful during a deductible phase or for uninsured patients.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs operates on a transparent markup model: manufacturing cost plus 15% markup plus $3 dispensing fee plus $5 shipping. Liraglutide pricing there has run significantly below brand prices, though availability fluctuates with supply chain conditions. The pharmacy is licensed in all 50 states and ships to patients with a valid prescription.

Canadian and International Mail-Order Pharmacies

The FDA generally does not pursue enforcement against patients importing a personal-use supply (typically a 90-day quantity) of a medication from a licensed Canadian pharmacy, per its Personal Importation Policy guidance. Canadian pharmacies sell brand-name Saxenda manufactured by Novo Nordisk at prices roughly 50 to 60% below US retail. Risks include shipping delays, customs holds, and the rare (but real) risk of counterfeit product from unverified international sources. Only use pharmacies verified by the Canadian International Pharmacy Association (CIPA) if choosing this route.

Clinical Trials as a Free-Access Pathway

Active clinical trials sometimes provide liraglutide at no cost to participants. ClinicalTrials.gov lists currently enrolling studies; as of January 2026, open trials include investigations of liraglutide in heart failure with preserved ejection fraction, NASH fibrosis, and polycystic ovary syndrome. Participants receive the drug, monitoring labs, and sometimes travel reimbursement at no charge.

The trade-off is randomization: you may be assigned to placebo. Open-label extension phases often provide continued access after the blinded period. Search ClinicalTrials.gov with the term "liraglutide" filtered to "Recruiting" status and your geographic radius to find options.

The HealthRX Access Decision Framework

The following stepwise framework is used by the HealthRX clinical team when a patient reports liraglutide affordability barriers. Work through each step before moving to the next.

Step 1. Confirm insurance formulary status. Call your insurer's pharmacy benefit line and ask whether Victoza or Saxenda is on formulary, what tier, and what the prior authorization criteria are. Request the formulary exception form if the drug is non-formulary.

Step 2. Apply the manufacturer savings card. If you have commercial insurance, the Novo Nordisk co-pay card can reduce costs to approximately $99/month for Saxenda. Apply at saxenda.com/savings before filling the first prescription.

Step 3. Check PAP eligibility. If uninsured or underinsured with income at or below 400% FPL, apply through NovoCare for free drug. Timeline is two to four weeks.

Step 4. Price generic alternatives. Ask your prescriber to write "generic acceptable" and check Cost Plus Drugs, GoodRx, and Amazon Pharmacy for current generic liraglutide pricing in your zip code.

Step 5. Use pre-tax accounts. Pay whatever remaining out-of-pocket cost exists through your HSA or FSA to recover 22 to 37% of the cost in tax savings depending on your bracket.

Step 6. Evaluate clinical trial enrollment. If none of the above closes the gap, search ClinicalTrials.gov for recruiting liraglutide trials near you.

Step 7. Consider therapeutic alternatives. If liraglutide remains unaffordable after all steps above, discuss with your clinician whether semaglutide (Ozempic/Wegovy) with its own access programs, or tirzepatide (Mounjaro/Zepbound) with its $550/month LillyDirect self-pay price, may fit your clinical profile and budget.

Cardiovascular and Metabolic Evidence Supporting Access Advocacy

When appealing an insurance denial, citing the clinical evidence directly strengthens your case. Two trials are most relevant.

LEADER Trial (Cardiovascular Outcomes)

The LEADER trial enrolled 9,340 patients with type 2 diabetes and high cardiovascular risk, randomizing them to liraglutide 1.8 mg daily or placebo. At a median follow-up of 3.8 years, liraglutide reduced the composite MACE endpoint (CV death, nonfatal MI, nonfatal stroke) by 13% (HR 0.87, 95% CI 0.78 to 0.97, P<0.001 for non-inferiority; P=0.01 for superiority) (Marso et al., NEJM 2016). CV death alone was reduced by 22%.

SCALE Obesity and Prediabetes Trial

The SCALE trial enrolled 3,731 adults with BMI >30 or BMI >27 with at least one weight-related comorbidity. Liraglutide 3.0 mg daily produced a mean weight loss of 8.0% from baseline vs. 2.6% with placebo at 56 weeks (P<0.001), and 63.2% of liraglutide-treated patients achieved ≥5% body-weight loss vs. 27.1% with placebo (Pi-Sunyer et al., NEJM 2015).

The ADA 2024 Standards of Care state directly: "For patients with type 2 diabetes and atherosclerotic cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of A1C." (ADA, Diabetes Care 2024). That language is the basis for overturning most prior authorization denials in the T2D-plus-CV-risk population.

Telehealth Prescribing and Access Considerations

The DEA's 2023 telemedicine prescribing rules do not restrict GLP-1 prescribing because liraglutide is not a controlled substance. A telehealth clinician can legally prescribe Victoza or Saxenda for a new patient in all 50 states without an in-person visit, as long as state medical board rules permit the prescriber's practice model. The FDA's telehealth FAQ confirms non-controlled drugs face no Ryan Haight Act restrictions.

Telehealth platforms often have established relationships with specialty pharmacies that carry current generic liraglutide stock, which can further reduce costs compared to retail chain pharmacies.